Scientists in the U.S. have demonstrated that long-term therapy with the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene helps to slow disease progression in a mouse model of one of the most common forms of muscular...
Incyte CEO Hervé Hoppenot scored a big pay raise in 2017, even after the FDA forced it and partner Eli Lilly to refile for approval of baricitinib, a highly anticipated rheumatoid arthritis drug that flubbed its first run at a green light.
On CNBC's "Fast Money Final Trade", Dan Nathan said he would start buying Target Corporation (NYSE: TGT).
Brian Kelly thinks Square Inc (NYSE: SQ) should be bought.
Karen Finerman is a little bit nervous about the market and she wants to buy...
Eli Lilly and Boehringer Ingelheim are gunning for a heart-failure nod for diabetes drug Jardiance. And if they can get it, they want to be able to talk up the product’s effects on exercise ability, too.
Since Eli Lilly CEO David Ricks took the helm last year, he’s shaken up management twice, launched new cost-cutting measures and instituted thousands of job cuts. And he collected a compensation package of nearly $16 million for his efforts.
Eli Lilly has some formidable competition coming in the GLP-1 diabetes class, so it’s wasting no time looking for growth avenues for its contender, Trulicity. And if new data are any indication, it may have just found one.
It’s been just five months since Eli Lilly breast cancer drug Verzenio hit the market, but the product has racked up its third approval, broadening its group of eligible patients and putting it on more even footing with rivals from Pfizer and...
Eli Lilly has halted a phase 2 rheumatoid arthritis trial after getting a midstudy glimpse at the data. The setback leaves Lilly and partner Hanmi Pharmaceutical to weigh whether it is worth moving the Bruton's TKI forward in other indications.
Oops! Unable to complete your request. Please refresh your browser.